The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
The use of the R6 transgenic mouse models of Huntington’s disease in attempts to develop novel therapeutic strategies
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979 · cited 2×
“Therefore, the idea that inclusions are protective against the toxic effects of expanded polyglutamine proteins has emerged.(9,10) However, even in case the protein aggregates allow the cells to survive longer, it is not clear to what extent they lead to disturbed cell function.”
BackgroundHistone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., et al. (2001) · Nature · doi:10.1038/35099568 · Cited by 1,228 · cited 1×
“Inhibitors of histone deacetylase (HDAC) can reverse the reduction in acetylated histones in a Drosophila model of HD and thereby reduce cell death.(88) HDAC inhibitors have also been tested in trials in R6/2 mice.”
BackgroundGauthier, L. R., Charrin, B. C., Borrell-Pagès, M., Dompierre, J. P., Rangone, H., Cordelières, F. P., De Mey, J., MacDonald, M. E., Leßmann, V., Humbert, S., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.018 · Cited by 1,178
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes
Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., Cataudella, T., Leavitt, B. R., Hayden, M. R., Timmusk, T., et al. (2003) · Nature Genetics · doi:10.1038/ng1219 · Cited by 979 · cited 1×
“In agreement with this concept, a reduced expression of NRSE-controlled neuronal genes, including BDNF, was observed in cellular and animal models of HD, as well as HD patients.(150) Reduction of BDNF protein in the caudate-putamen of HD patients ranges from 53–82%.”
BackgroundNeuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease
Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., & Beal, M. F. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04389.2000 · Cited by 522
Choo, Y. S. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh162 · Cited by 515 · cited 1×
“Studies with purified mitochondria demonstrated that mutant huntingtin can associate with the outer mitochondrial membrane and directly induce the opening of the mitochondrial permeability transition pore with simultaneous release of cytochrome C.(117) In addition, deficits of mitochondrial complexes I, II, and IV hav…”
BackgroundCha, J.-H. J., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., Penney, J. B., Bates, G. P., & Young, A. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6480 · Cited by 504
Sittler, A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1307 · Cited by 442 · cited 1×
“Nevertheless, radicicol, a fungal antibiotic, and geldanamycn, a benzoquinone ansamycin, known to bind to HSP90 and to induce expression of HSP40 and HSP70 chaperones, have both been found to increase HSP response in culture models of HD and inhibit huntingtin aggregation.(75,77) However, these drugs have not yet been…”
BackgroundNonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
Turmaine, M., Raza, A., Mahal, A., Mangiarini, L., Bates, G. P., & Davies, S. W. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.110078997 · Cited by 430
Cited by
Lipid peroxidation and neurodegenerative disease
Reed, T. T. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.027 · Cited by 379
Flavonoids and their role in oxidative stress, inflammation, and human diseases
Jomova, K., Alomar, S. Y., Valko, R., Liska, J., Nepovimova, E., Kuca, K., & Valko, M. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111489 · Cited by 362
Creatine: Endogenous Metabolite, Dietary, and Therapeutic Supplement
Brosnan, J. T., & Brosnan, M. E. (2007) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.27.061406.093621 · Cited by 347
S-Glutathionylation: From Molecular Mechanisms to Health Outcomes
Xiong, Y., Uys, J. D., Tew, K. D., & Townsend, D. M. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3540 · Cited by 314
“The R6 transgenic mouse model consists of the R6/1 and R6/2 lines, with the R6/2 being the better characterized of the two for the study of HD (154).”
MethodHarnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein
Bauer, P. O., Goswami, A., Wong, H. K., Okuno, M., Kurosawa, M., Yamada, M., Miyazaki, H., Matsumoto, G., Kino, Y., Nagai, Y., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1608 · Cited by 280
The biosynthesis, signaling, and neurological functions of bile acids
Kiriyama, Y., & Nochi, H. (2019) · Biomolecules · doi:10.3390/biom9060232 · Cited by 204
“Secondly, R6/2 transgenic mice possess a genomic fragment containing exon 1 of the human Huntingtin gene, which carries 144 CAG repeats, and are the most widely used model of Huntington’s disease [181,183].”
BackgroundThe pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies
Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178
Crapser, J. D., Ochaba, J., Soni, N., Reidling, J. C., Thompson, L. M., & Green, K. N. (2020) · Brain · doi:10.1093/brain/awz363 · Cited by 157
“, 2014), R6/2 mice display marked striatal atrophy (Hansson et al., 1999; Li et al., 2005) similar to humans.”
BackgroundTransglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver
Elli, L., Bergamini, C. M., Bardella, M. T., & Schuppan, D. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2008.12.095 · Cited by 145
“ity have been developed and mainly tested in vitro [6,132–136].”
BackgroundGodinho, B. M. D. C., Ogier, J. R., Darcy, R., O’Driscoll, C. M., & Cryan, J. F. (2013) · Molecular Pharmaceutics · doi:10.1021/mp3003946 · Cited by 126
Potential biomarkers to follow the progression and treatment response of Huntington’s disease
Disatnik, M.-H., Joshi, A. U., Saw, N. L., Shamloo, M., Leavitt, B. R., Qi, X., & Mochly-Rosen, D. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160776 · Cited by 58
“, 1993), there has been considerable effort toward developing therapeutic strategies for HD, and several compounds have shown beneficial effects in various HD cell and transgenic mouse models (Li et al., 2005; Ray and Shoulson, 2011; Guo et al., 2013).”
BackgroundPurinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy
Oliveira-Giacomelli, Á., Naaldijk, Y., Sardá-Arroyo, L., Gonçalves, M. C. B., Corrêa-Velloso, J., Pillat, M. M., de Souza, H. D. N., & Ulrich, H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00325 · Cited by 50
Gubert, C., Love, C. J., Kodikara, S., Mei Liew, J. J., Renoir, T., Lê Cao, K.-A., & Hannan, A. J. (2022) · iScience · doi:10.1016/j.isci.2021.103687 · Cited by 41
Duarte, A. I., Sjögren, M., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Björkqvist, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-27121-w · Cited by 25
Crook, Z. R., & Housman, D. E. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204542109 · Cited by 23
Metadata
- Authors
- Li, J. Y., Popovic, N., & Brundin, P.
- Venue
- NeuroRX
- Published
- 2005-07
- Volume
- 2
- Issue
- 3
- Pages
- 447-464
- ISSN
- 1545-5343 (ISSN-L)
- OpenAlex
- W2027835288
- Cited by
- 211
- References
- 18
- FWCI
- 1.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.